equis - Articles
Altrenogest
Synonym(s): Progestagen
Introduction
Name
- Altrenogest.
Class of drug
- Synthetic progestogen.
Description
Chemical name
- 17-alpha-allyl-17-beta-hydroxyestra-4,9,11-trien-3-one (allytenbolone).
Molecular formula
- C21H26O2.
Molecular weight
- 310.43.
Physical properties
- Licensed form in the UK is an oral solution, which is clear and light yellow.
- In some other countries, eg Australia, a licensed injectable form is also available.
Storage requirements
- Should be stored in its original bottle and dispensed with care using a syringe and protective clothing (see 'Precautions' below).
- Because of its potential to cause disease in humans and to contaminate the feed of horses other than those being treated (see ‘Precautions’ below), it should be stored safely with particular care well away from children and where it cannot be handled accidentally by anyone not wearing protective clothing, nor by women of childbearing age or those with particular medical conditions.
Uses
Subscribe To View
This article is available to subscribers.
Try a free trial today or contact us for more information.
Administration
Subscribe To View
This article is available to subscribers.
Try a free trial today or contact us for more information.
Pharmacokinetics
Subscribe To View
This article is available to subscribers.
Try a free trial today or contact us for more information.
Precautions
Subscribe To View
This article is available to subscribers.
Try a free trial today or contact us for more information.
Withdrawal Periods
Subscribe To View
This article is available to subscribers.
Try a free trial today or contact us for more information.
Adverse Reactions
Subscribe To View
This article is available to subscribers.
Try a free trial today or contact us for more information.
Further Reading
Publications
Refereed papers
- Recent references from PubMed and VetMedResource.
- De Mestre A M, Rose B V, Chang YM, Wathes D C, Verheyen K L P (2019) Multivariable analysis to determine risk factors associated with early pregnancy loss in thoroughbred broodmares. Theriogenology 124, 18-23 PubMed.
- McConaghy F F, Green L A, Colgan S, Morris L H (2016) Studies of the pharmacokinetic profile, in vivo efficacy and safety of injectable Altrenogest for the suppression of oestrus in mares. Aust Vet 94 (7), 248-55 PubMed.
- Willmann C, Schuler G, Hoffmann B, Parvizi N & Aurich C (2011) Effects of age and Altrenogest treatment on conceptus development and secretion of LH, progesterone and eCG in early-pregnant mares. Theriogenology 75 (3), 421-8 PubMed.
- Storer W, Thompson D L, Gilley R M & Burns P J (2009) Evaluation of injectable sustained release progestin formulations for suppression of estrus and ovulation in mares. J Equine Vet Sci 29 (1), 33-36 VetMedResource.
- Goolsby H A, Brady H A & Prien S D (2004) The off-label use of Altrenogest in stallions: a survey. J Equine Vet Sci 24 (2), 72-75 VetMedResource.
- Daels P F, McCue P M, DeMoraes M J & Hughes J P (1996) Persistence of the luteal phase following ovulation during Altrenogest treatment in mares. Theriogenology 46 (5), 799-811 PubMed.
Other sources of information
- The NOAH Compendium of datasheets of licensed veterinary medicines. Available at: https://www.noahcompendium.co.uk.
- BHA Notice: Altrenogest update. Available at: https://www.britishhorseracing.com (pdf download).
- Veterinary Medicines Directorate. Adverse Reaction Reporting. Available at: https://www.vmd.defra.gov.uk.
- Veterinary Medicines Directorate. Questions and Answers on FDA's Adverse Event Reporting System (FAERS). Available at: https://www.fda.gov/drugs.